Naurex Secures $18,000,000 Series A Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    1801 Maple Ave. Evanston, IL 60201
  • Company Description
    Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR).
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Naurex will use the proceeds from the Series A financing primarily for the Phase II trial of its lead compound, GLYX-13, a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), and also to advance its second-generation GFPA program.
  • M&A Terms
  • Venture Investor
    Adams Street Partners
  • Venture Investor
    Latterell Venture Partners
  • Venture Investor
    Takeda Ventures
  • Venture Investor
    Shire Pharmaceuticals
  • Venture Investor

Trending on Xconomy